Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital technology

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

The two companies will withdraw patent infringement proceedings filed with the US and Japan

- PMLiVE

MHRA grants approval for AstraZeneca’s Evusheld in the UK

It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives FDA approval

An estimated 2.3 million patients were diagnosed with breast cancer in 2020

Consumer-driven Healthcare in the Digital Age

Dr. Gil Blander, Co-founder & Chief Scientific Officer at InsideTracker, explores consumer-driven healthcare, the use of big data and AI for creating personalized health protocols, the trillion-dollar “longevity economy,” and...

Impetus Digital

- PMLiVE

Ovarian Cancer Commitment announced to improve patient care

The coalition was announced by ENGAGe, ESGO and AstraZeneca in a call to improve ovarian cancer care

Gamifying Remote Patient Monitoring

Dr. Emilia Molimpakis, CEO & Co-founder of Thymia, shares how their platform uses video games based on neuropsychology, alongside analyses of facial microexpressions and speech, to quickly, accurately, and objectively...

Impetus Digital

Social Health Prescription: Connecting People, Empowering Patients, & Improving Outcomes

Lynda Brown-Ganzert, Founder & CEO of Curatio, discusses the concept of social health prescription and the inspiration behind Curatio. She also explores questions such as how AI and “intelligent matchmaking” can be leveraged...

Impetus Digital

- PMLiVE

Enhertu trial results show significant improvement for breast cancer patients

The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study

- PMLiVE

AZ’s Saphnelo receives EU approval for systemic lupus erythematosus

There are an estimated 250,000 people living with SLE in Europe and this is the first new drug to gain EU approval in over ten years

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

Video: Emotion AI

Artificial intelligence is revolutionising the way we conduct healthcare market research.

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links